Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

• Register: ClinicalTrials.gov
• Last refreshed on: 7 January 2013
• Main ID: NCT00853073
• Date of registration: 26/02/2009
• Primary sponsor: Wills Eye
• Public title: Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions? Avastin
• Scientific title: Does a New Add on (or Adjunctive) Therapy Used in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
• Date of first enrolment: February 2009
• Target sample size: 63
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00853073
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: Marlene R Moster, MD
• Affiliation: Wills Eye

Key inclusion & exclusion criteria

Inclusion Criteria:

- require glaucoma bleb needle revision with Mitomycin-C

Exclusion Criteria:

- pregnant, nursing, or not using adequate contraception

- other glaucoma eye surgery involving tube shunts

- prior retinal detachments surgery with scleral buckle

- infection, inflammation, or any abnormality preventing eye pressure measurement

- enrolled in another investigational study



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Glaucoma

Intervention(s)

Drug: bevacizumab

Other: balanced salt solution

Primary Outcome(s)

intraocular pressure (IOP) [Time Frame: 6 months]

Secondary Outcome(s)

improvement in filtering blebs morphology [Time Frame: 6 months]

Secondary ID(s)

08-867

Source(s) of Monetary Support

Please refer to primary and secondary sponsors